Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Dolca Thomas"'
Autor:
Sibel Ucpinar, Borje Darpo, Ann Neale, Philip Nunn, Jin Shu, Katherine A. Chu, Marianne Kavanagh, Hongqi Xue, Pasit Phiasivongsa, Dolca Thomas, Patrick F. Smith
Publikováno v:
Clinical and Translational Science, Vol 15, Iss 6, Pp 1507-1518 (2022)
Abstract This study aimed to define the clinically relevant supratherapeutic dose of rilzabrutinib, an oral Bruton tyrosine kinase (BTK) inhibitor, and evaluate potential effects of therapeutic and supratherapeutic exposures on cardiac repolarization
Externí odkaz:
https://doaj.org/article/3418278264b64f71bc273037eb1ad05f
Autor:
Till Strowig, Fabienne Brilot, Frida Arrey, Gwenola Bougras, Dolca Thomas, William A Muller, Christian Münz
Publikováno v:
PLoS Pathogens, Vol 4, Iss 2, p e27 (2008)
Cells of the innate immune system act in synergy to provide a first line of defense against pathogens. Here we describe that dendritic cells (DCs), matured with viral products or mimics thereof, including Epstein-Barr virus (EBV), activated natural k
Externí odkaz:
https://doaj.org/article/f23bc3d4b4214c4ea2176598f78ce1d1
Autor:
David J. Kuter, Merlin Efraim, Jiri Mayer, Marek Trněný, Vickie McDonald, Robert Bird, Thomas Regenbogen, Mamta Garg, Zane Kaplan, Nikolay Tzvetkov, Philip Y. Choi, A.J. Gerard Jansen, Milan Kostal, Ross Baker, Jaromir Gumulec, Eun-Ju Lee, Ilona Cunningham, Isaac Goncalves, Margaret Warner, Ralph Boccia, Terry Gernsheimer, Waleed Ghanima, Olga Bandman, Regan Burns, Ann Neale, Dolca Thomas, Puneet Arora, Beiyao Zheng, Nichola Cooper
Publikováno v:
New England Journal of Medicine, 386(15), 1421-1431. Massachussetts Medical Society
BACKGROUND Rilzabrutinib, an oral, reversible covalent inhibitor of Bruton's tyrosine kinase, may increase platelet counts in patients with immune thrombocytopenia by means of dual mechanisms of action: decreased macrophage (Fcγ receptor)-mediated p
Autor:
Sibel, Ucpinar, Borje, Darpo, Ann, Neale, Philip, Nunn, Jin, Shu, Katherine A, Chu, Marianne, Kavanagh, Hongqi, Xue, Pasit, Phiasivongsa, Dolca, Thomas, Patrick F, Smith
Publikováno v:
Clinical and Translational Science. 15:1507-1518
This study aimed to define the clinically relevant supratherapeutic dose of rilzabrutinib, an oral Bruton tyrosine kinase (BTK) inhibitor, and evaluate potential effects of therapeutic and supratherapeutic exposures on cardiac repolarization in healt
Autor:
Cherie Tracy Ng, Leslie Chinn, Lisette M Acevedo, Dalena Chu, Maple Fung, Joel Rothman, Stephen Connelly, Dolca Thomas, Corey Cutler, John Koreth
Publikováno v:
Transplantation and Cellular Therapy. 28:S287-S288
Autor:
John Koreth, Edmund K. Waller, Ryotaro Nakamura, Alison W. Loren, Leslie Chinn, Cherie Tracy Ng, Lisette M Acevedo, Dalena Chu, Maple Fung, Joel Rothman, Stephen Connelly, Dolca Thomas, Corey Cutler
Publikováno v:
Transplantation and Cellular Therapy. 28:S288
Autor:
Dalena Chu, Leslie Chinn, Jerome Ritz, John Koreth, Stephen Connelly, Corey Cutler, Lisette M. Acevedo, Cherie Ng, M. Fung, Joel Rothman, Dolca Thomas
Publikováno v:
Blood. 138:2891-2891
Introduction: Itolizumab is a first-in-class monoclonal antibody against the co-stimulatory receptor CD6 that blocks its interaction with activated leukocyte cell adhesion molecule (ALCAM), thereby inhibiting T effector (T eff) cell activity and traf
Autor:
Olga Bandman, J. Gumulec, Milan Kostal, A.J. Gerard Jansen, Terry B. Gernsheimer, Ahmed Daak, Ann Neale, Regan Burns, Fareha Iqbal, Philip Young-Ill Choi, David J. Kuter, Ross I. Baker, Nichola Cooper, Mamta Garg, Timothee Sourdille, Waleed Ghanima, Jiří Mayer, Mengjie Yao, Vickie McDonald, Puneet Arora, Zane Kaplan, Nikolay Tzvetkov, Dolca Thomas, Merlin Efraim, Robert Bird
Publikováno v:
Blood. 138:14-14
Introduction: Key characteristics of immune thrombocytopenia (ITP) include immune-mediated platelet destruction/impaired production, with resultant thrombocytopenia and increased bleeding risk. Durable response to current therapies remains an unmet n
Autor:
Dolca Thomas, Thomas Regenbogen, Zane Kaplan, Nichola Cooper, Regan Burns, Robert Bird, David J. Kuter, Merlin Efraim, Mamta Garg, Jiri Mayer, Ann Neale, Vickie McDonald, Olga Bandman
Publikováno v:
Blood. 136:13-14
Introduction: Rilzabrutinib is an oral, reversible, covalent inhibitor of Bruton tyrosine kinase (BTK) that targets underlying disease mechanisms of platelet destruction without inhibiting platelet aggregation (common with ibrutinib). The mechanisms
Autor:
Nikolay Tzvetkov, Dolca Thomas, Milan Kostal, Merlin Efraim, Roman Hájek, Nichola Cooper, Jiri Mayer, Marek Trněný, David J. Kuter, Vickie McDonald, Olga Bandman, Eun-Ju Lee, Regan Burns, Ralph V. Boccia, Ann Neale
Publikováno v:
Blood. 134:87-87
Background: Immune thrombocytopenia (ITP) is characterized by immune-mediated platelet destruction and impairment of platelet production, leading to downstream thrombocytopenia, a predisposition to bleeding, and adverse impact on patient quality of l